Heidelberg Pharma AG

Board/Management Information • Oct 1, 2007

News Details

Corporate | 1 October 2007 15:58

WILEX AG: Supervisory Board appoints Thomas Borcholte as Chief Business Officer and member of the Executive Management Board of WILEX AG

WILEX AG / Change of Personnel

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Supervisory Board appoints Thomas Borcholte as Chief Business Officer and
member of the Executive Management Board of WILEX AG

Munich, 1 October 2007. The Supervisory Board of Munich-based
biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock
Exchange/Prime Standard) today appointed Dr. Thomas Borcholte as member of
the Executive Management Board and Chief Business Officer (CBO). Dr.
Borcholte is responsible for Business Development and will implement the
Company’s commercialisation strategy. He has over 20 years experience in
leading positions in business development and marketing within the
pharmaceutical and biotechnology industries. Most recently, Dr. Borcholte
was Chief Marketing and Sales Officer at Topotarget S/A Copenhagen and
member of the Executive Board of TopoTarget Germany AG, Frankfurt. He
previously held positions at BIOGEN GmbH, Germany and Glaxo Wellcome GmbH,
Hamburg. He graduated in biochemistry at the University of Hannover and
received his PhD in human biology.

Dr. David Ebsworth, Chairman of the Supervisory Board of WILEX AG,
commented: 'Thomas Borcholte has extensive experience, expertise and an
excellent network as well as an impressive track record in business
development and marketing. The supervisory board is delighted that
Dr. Borcholte has joined the Executive team.'

About WILEX AG
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a
team of physicians and oncologists from the Technical University of Munich.
WILEX is focused on the development of new cancer therapies based on
antibodies and small molecules. The therapeutic approach of WILEX targets
the prevention of growth, spread and the metastasis of malignant tumours
and the destruction of malignant tumours in the body. The late stage
multi-product portfolio includes both drug and medical product candidates
ranging from research to late stage clinical development. Currently the
following compounds are in clinical development: WX-G250 (development name:
RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The Company’s strategy is to
develop WILEX into a commercially successful biopharmaceutical Company with
a broad portfolio of new drugs and medical products for the treatment of
cancer. WILEX AG is listed on the Frankfurt Stock Exchange in the Official
Market Segment (Amtlicher Markt) / Prime Standard.
ISIN DE0006614720 / WKN 661472 / Symbol WL6
01.10.2007 Financial News transmitted by DGAP

---

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---